Development of liposomal formulations for the encapsulation of mucolytics: combined treatments against respiratory diseases

FEAS, DANIELA AGUSTINA; ADRIANA LOPES DA SILVIA; PATRICIA RIEKEN MACEDO ROCO; MORALES, MARCELO; ALONSO, SILVIA DEL VALLE; CHIARAMONI, NADIA SILVIA

Tucuman

Congreso; III Latin American Federation of Biophysical Societies (LAFeBS) ? IX IberoAmerican Congress of Biophysics ? XLV Reunion Anual SAB; 2016

Respiratory diseases are very common and affect a large part of the population worldwide. The key for the efficiency enhancement of treatments is thattherapeutic agents reach the target lung tissue. In order to achieve this, barriers such as lung architecture, defense mechanisms and mucus must be overcome.Mucus is a viscoelastic gel that protects the respiratory tract. Mucolytic agents break down the gel structure of mucus and decrease its elasticity and viscosity.One of the most common mucolytic is L-cysteine, which proves to highly reduce in vitro mucus viscosity. Other molecule groups with mucolytic activity includeDNase enzymes, which are mostly used in Cystic Fibrosis treatments, such as dornase α.INTRODUCTIONLungs are covered with a surfactant layer, which main component is DPPC (dipalmitoyl-sn-glycero-3-phosphatidylcholine); other minor components are PMPC (1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine) and POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine).Based on this, the aim of this work was the development of mucolytic transporters, whichencapsulate dornase α and L-cysteine. Phospholipids of the surfactant layer were used forliposomal formulations in order to improve interaction between these transporters and lungtissue